^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    COL3A1 overexpression

    i
    Other names: COL3A1, Collagen Type III Alpha 1 Chain, Ehlers-Danlos Syndrome Type IV, Autosomal Dominant, Collagen, Type III, Alpha 1, Collagen Alpha-1(III) Chain, EDS4A, Alpha-1 Type III Collagen, Alpha1 (III) Collagen, Collagen, Fetal, EDSVASC, PMGEDSV
    almost3years
    The characterization of the sensitive ovarian cancer cell lines A2780 and W1 in response to ovarian CAFs. (PubMed, Biochem Biophys Res Commun)
    We demonstrated that the process of drug resistance in ovarian cancer cells is launched by CAFs. CAFs not only simulate cancer cells to produce drug transporters and specific enzymes production, but also remodel the TME to increase drug resistance. We believe that cancer progression and migration is due to the CAFs po-tumorigenic activity.
    Preclinical • Journal
    |
    FN1 (Fibronectin 1) • CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8) • ABCC5 (ATP Binding Cassette Subfamily C Member 5) • COL3A1 (Collagen Type III Alpha 1 Chain)
    |
    COL3A1 overexpression
    almost3years
    The lncRNA XIST/miR-29b-3p/COL3A1 axis regulates central carbon metabolism in head and neck squamous cell carcinoma and is associated with poor tumor prognosis. (PubMed, Ann Transl Med)
    At the same time, we found that the lncRNA XIST/miR-29b-3p/COL3A1 axis may regulate the central carbon metabolism of HNSCC and is associated with poor prognosis. These findings point to a potential target for developing HNSCC anticancer therapies.
    Journal
    |
    KDR (Kinase insert domain receptor) • COL3A1 (Collagen Type III Alpha 1 Chain) • PFKP (Phosphofructokinase, Platelet) • XIST (X Inactive Specific Transcript)
    |
    EGFR mutation • KDR expression • COL3A1 overexpression